The role of procalcitonin in sepsis

Efficacy of procalcitonin level measurement in diagnosis of early antimicrobial resistance in patient with sepsis in emergency department

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT201102065774N1

Enrollment

150

Registered

2011-07-24

Start date

2011-07-23

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: Sepsis. Condition 2: procalcitonin. Sequelae of infectious and parasitic diseases Abnormal findings on examination of blood, without diagnosis

Interventions

Immunoluminoassy of serum procalcitonin in patient with sepsis, Blood sampling, Lumbar puncture.

Diagnosis

Immunoluminoassy of serum procalcitonin in patient with sepsis, Blood sampling, Lumbar puncture

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Inclusion criteria: All patients with clinical findings suggesting sepsis, All patients with clinical findings of systemic inflammatory response syndrome Exclusion criteria: All patients with clinical findings of systemic inflammatory response syndrome from non bacterial origin, viral or parasitic infections, patients who receive corticosteroids on immunosuppressive drugs, history of immunodeficiency, patient with central venous catheter and premature infant

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Procalcitonin. Timepoint: before and 6 hr and 24 hr after empiric antibiotic administration. Method of measurement: Immunoluminoassay ng/mL.	—

Secondary

Measure	Time frame
Antibiogram. Timepoint: One time. Method of measurement: Resistantant, sensitive.;Empiric antibiotic. Timepoint: one time, after blood sampling withdrawn. Method of measurement: based on united state infectious disease guideline.;Time of clinical sign improved. Timepoint: Daily. Method of measurement: Clinical sign(fever).;Prognosis(death). Timepoint: Death. Method of measurement: Clinically.;Prognosis(life). Timepoint: Life. Method of measurement: Clinically.;Thyroid tumor. Timepoint: One time. Method of measurement: Clinical and laboratory investigation.;Immunosuppression. Timepoint: One time. Method of measurement: Clinical and laboratory investigation.	—

Measure

Time frame

Antibiogram. Timepoint: One time. Method of measurement: Resistantant, sensitive.;Empiric antibiotic. Timepoint: one time, after blood sampling withdrawn. Method of measurement: based on united state infectious disease guideline.;Time of clinical sign improved. Timepoint: Daily. Method of measurement: Clinical sign(fever).;Prognosis(death). Timepoint: Death. Method of measurement: Clinically.;Prognosis(life). Timepoint: Life. Method of measurement: Clinically.;Thyroid tumor. Timepoint: One time. Method of measurement: Clinical and laboratory investigation.;Immunosuppression. Timepoint: One time. Method of measurement: Clinical and laboratory investigation.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAli Arhami Dolatabadi

Shahid Beheshti University of Medical Sciences

ali_arhami@sbmu.ac.ir; aliarhami@yahoo.com00982177558081- 00982188251234

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026